•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Investors in ImmunityBio, Inc. (NasdaqGS: IBRX) who purchased shares between January 19, 2026 and March 24, 2026 are being reminded of an upcoming deadline to seek lead plaintiff status in a securities class action lawsuit. The deadline to file lead plaintiff applications is May 26, 2026.
The case is pending in the United States District Court for the Central District of California.
According to the notice, ImmunityBio and certain executives are charged with failing to disclose material information during the class period, in alleged violation of federal securities laws.
On March 24, 2026, a warning letter dated March 13, 2026 from the U.S. Food and Drug Administration to CEO Richard Adcock was made public. The letter stated that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act.
The notice also reports that the FDA letter said the violations “are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.”
Following the news, ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.
The lawsuit is captioned Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.
Investors who wish to serve as lead plaintiff must petition the court by May 26, 2026.
Kahn Swick & Foti, LLC (KSF) and partner Lewis Kahn are described as offering investors the opportunity to discuss legal rights and how the case may affect potential recovery for economic loss. The notice states that contact is available toll-free at 1-877-515-1850 or by email at lewis.kahn@ksfcounsel.com.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
